Drug intelligence / Profile preview

Aliaxin FL

Development stage
Unknown
Lead developer
IBSA Farmaceutici Italia
Modality
Recombinant Proteins and Enzymes
Administration
Intradermal, Submucosal
01

Overview

**Aliaxin FL** is a sterile, viscoelastic monophasic gel dermal filler containing **cross-linked hyaluronic acid** at a concentration of 25 mg/mL, buffered with phosphate and water for injection[1][3][4][5]. It is primarily designed to treat **fine lines** and perform **lip enhancements**, restoring subtle volume, correcting minor asymmetries, and improving definition, especially in the vermillion border of the lips[1][3][5][7]. The hyaluronic acid is ultra-pure and produced via patented bio-fermentation of Streptococcus Zooepidemicus, characterized by high tissue integration, stability, and a low percentage of cross-linking agent BDDE, offering safety and minimal residue[4]. The mechanism of action is the **physicochemical restoration of volume and hydration** through injection into the superficial to mid-dermis or labial mucosa, with biocompatibility and biodegradability ensuring transient effects lasting approximately 6–12 months[1][3]. No allergy testing is needed, and adverse reactions are minimal and transient; the product is CE-marked and produced under GMP and ISO certification.

Brand names
Aliaxin FL
Other names
Firm LipsAliaxin FL Firm LipsAliaxin FL LipsAliaxin FL Fine Lines

Beyond the preview

Go deeper on Aliaxin FL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aliaxin FL.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call